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Exposure of pregnant women and young chil-
dren to organophosphate insecticides remains a
major concern in light of their developmental
neurotoxicity (Jamal et al. 2002; Landrigan
2001; Landrigan et al. 1999; May 2000;
National Research Council 1993; Physicians
for Social Responsibility 1995; Pope 1999;
Ray and Richards 2001; Rice and Barone
2000; Slotkin 1999). Although recent restric-
tions have been placed on its use in the United
States [U.S. Environmental Protection Agency
(EPA) 2000], chlorpyrifos (CPF) remains one
of the most heavily used insecticides world-
wide. Of the adverse effects of CPF on neu-
rodevelopment, cholinergic systems represent a
major focus, logically because its systemic toxi-
city results from inhibition of cholinesterase
and the consequent cholinergic hyperstimula-
tion (Barone et al. 2000; Mileson et al. 1998;
Pope 1999; Ray and Richards 2001; Slotkin
1999). Nevertheless, it is increasingly clear that
CPF alters brain development through a
panoply of noncholinergic mechanisms, super-
imposed on cholinesterase inhibition (Barone
et al. 2000; Garcia et al. 2001, 2002, 2003;
Lassiter et al. 1998, 2002; Monnet-Tschudi et
al. 2000; Moser and Padilla 1998; Pope 1999;
Qiao et al. 2001, 2002, In press; Rice and
Barone 2000; Slotkin 1999). Accordingly,
recent studies have begun to explore neuro-
transmitter pathways other than the choliner-
gic system that may be adversely affected by
developmental exposure to CPF (Bloomquist
et al. 2002; Dam et al. 1999a, 1999b; Karen et
al. 2001; Raines et al. 2001; Sachana et al.
2001; Slotkin et al. 2002).
In an earlier study (Aldridge et al. 2003),
we found that, during discrete prenatal and
early postnatal periods, CPF elicits immediate
alterations in the ontogenesis of serotonin
(5HT) projections, characterized by adverse
effects on the 5HT presynaptic transporter,
5HT receptor binding sites, and cell signaling
mediated by 5HT receptors. These effects are
important for three reasons. First, they were
elicited at CPF exposures below the threshold
for any signs of systemic toxicity and, indeed,
below the levels necessary to elicit signiﬁcant
inhibition of cholinesterase in the fetal brain
(Qiao et al. 2002). Second, 5HT serves as a
neurotrophin, inﬂuencing cell differentiation
and regional cytoarchitecture during brain
development (Azmitia 2001; Dreyfus 1998;
Lauder 1985; Levitt et al. 1997; Turlejski
1996; Weiss et al. 1998; Whitaker-Azmitia
1991, 2001); accordingly, perturbations of
5HT may be one of the contributors to non-
cholinergic mechanisms of CPF-induced
neurobehavioral anomalies. Finally, it has been
suggested that environmental toxicants that
evoke long-term changes in the programming
of 5HT function may contribute to appetitive
and affective disorders, and consequent
increases in the incidence of obesity, diabetes,
and depression (Slikker and Schwetz 2003;
Toschke et al. 2002; von Kries et al. 2002).
The present study was undertaken to
determine if developmental CPF exposure
leads to altered 5HT synaptic function in
adulthood. We evaluated four different treat-
ment windows ranging from the neural tube
stage [gestational days (GD) 9–12] and the
late gestational period (GD17–20) through
postnatal phases of terminal neuronal differen-
tiation and synaptogenesis [postnatal days
(PN) 1–4 and 11–14]; these are the same
treatment windows examined for short-term
effects in our earlier study (Aldridge et al.
2003). We chose doses that would enable us
to determine whether the threshold for effects
on 5HT systems lies below that for systemic
toxicity and/or inhibition of cholinesterase
(Aldridge et al. 2003; Garcia et al. 2003; Qiao
et al. 2002; Slotkin 1999, In press). When the
rats reached adulthood (PN60), we examined
factors that are critical to the functioning of
5HT synapses, all of which had been found to
be affected in the immediate posttreatment
period after developmental CPF exposure
(Aldridge et al. 2003; Raines et al. 2001). The
presynaptic 5HT transporter (5HTT) is a bio-
marker for the concentration of 5HT nerve
terminals and is responsible for regulating the
concentration of 5HT in the synapse (Cooper
et al. 1996). Cell signaling is controlled
through the actions of 5HT receptors; we
examined two receptor subtypes, 5HT1A and
5HT2. Finally, we examined the ability of
5HT receptors to control signaling through
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Developmental Exposure to Chlorpyrifos Elicits Sex-Selective Alterations of
Serotonergic Synaptic Function in Adulthood: Critical Periods and Regional
Selectivity for Effects on the Serotonin Transporter, Receptor Subtypes, 
and Cell Signaling
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During brain development, serotonin (5HT) provides essential neurotrophic signals, and in earlier
work, we found that developmental exposure to chlorpyrifos (CPF) elicits short-term changes in
5HT systems. In the present study, we evaluated the effects in adulthood after CPF exposures from
the neural tube stage [gestational days (GD) 9–12] and the late gestational period (GD17–20)
through postnatal neuronal differentiation and synaptogenesis [postnatal days (PN) 1–4 and 11–14],
using treatments below the threshold for systemic toxicity. With exposure on GD9–12, CPF elicited
global elevations in 5HT1A and 5HT2 receptors and in the 5HT presynaptic transporter. The
GD17–20 treatment elicited larger effects that displayed selectivity for regions with 5HT nerve ter-
minals and that were preferential for males. Although similar receptor up-regulation was seen after
PN1–4 exposure, the effects were larger in regions with 5HT cell bodies; in addition, the presynaptic
transporter was down-regulated in the nerve terminal zones of females. The PN11–14 exposure had
much smaller effects on receptors but still elicited transporter suppression with the same regional
and sex selectivity. Although CPF exposure on GD17–20, PN1–4, or PN11–14 altered the ability of
5HT to modulate adenylyl cyclase, this change did not correspond with the effects on 5HT recep-
tors, suggesting an additional set of effects on proteins that transduce the 5HT signal. Our results
indicate that CPF elicits long-lasting changes in 5HT receptors, the presynaptic 5HT transporter,
and 5HT-mediated signal transduction after exposure in discrete developmental windows that range
from the neural tube stage through synaptogenesis. These effects are likely to contribute to neuro-
behavioral teratology of CPF. Key words: adenylyl cyclase, brain development, chlorpyrifos,
organophosphate insecticides, serotonin receptors, serotonin transporter, sex-selective effects.
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[Online 4 November 2003]adenylyl cyclase (AC), the enzyme responsible
for generation of cyclic AMP. The two sub-
types evaluated here converge on the control of
AC through both stimulatory and inhibitory
mechanisms (Barnes and Sharp 1999; Duncan
et al. 1999; Morin et al. 1992; Raymond et al.
1999; Rovescalli et al. 1993), so we evaluated
the net balance of the AC response to 5HT
itself. Determinations were made in brain
regions with major 5HT terminal ﬁelds (cere-
bral cortex, hippocampus, striatum) as well as
those containing 5HT cell bodies (midbrain,
brainstem).
Materials and Methods
Animal treatments. All experiments using live
animals were carried out in accordance with
the declaration of Helsinki and with the Guide
for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources
1996) as adopted and promulgated by the
National Institutes of Health. Timed-preg-
nant Sprague–Dawley rats (Zivic Laboratories,
Pittsburgh, PA) were housed in breeding
cages, with a 12-hr light/dark cycle and with
free access to food and water. CPF (Chem
Service, West Chester, PA) was dissolved in
dimethylsulfoxide to provide rapid and com-
plete absorption (Whitney et al. 1995) and
was injected subcutaneously in a volume of
1 mL/kg body weight; control animals
received vehicle (DMSO) injections on the
same schedules. For exposure on GD9–12 or
GD17–20, dams were injected daily with CPF
at 1 or 5 mg/kg body weight. These doses
span the threshold for inhibition of fetal brain
cholinesterase activity, fetal growth impair-
ment, and reduced maternal weight gain, all of
which become evident at ≥ 5 mg/kg (Garcia
et al. 2003; Qiao et al. 2002). On the day of
birth, all pups were randomized within their
respective treatment groups and redistributed
to the dams with a litter size of 10 to maintain
a standard nutritional status. Randomization
was repeated at intervals of several days, and in
addition, dams were rotated among litters to
distribute any maternal caretaking differences
randomly across litters and treatment groups.
Animals were weaned on PN21. On PN60,
one male and one female were selected from
each litter and were decapitated. The cerebel-
lum, which is sparse in 5HT projections, was
removed and the brain was dissected into cere-
bral cortex, hippocampus, striatum, midbrain,
and brainstem. Tissues were frozen with liquid
nitrogen and stored at –45°C.
For studies of CPF effects in the ﬁrst few
days after birth, animals were given a subcuta-
neous injection of 1 mg/kg daily on PN1–4;
for studies in older animals, which tolerate
higher doses (Campbell et al. 1997; Pope and
Chakraborti 1992; Pope et al. 1991; Whitney
et al. 1995), daily treatment with 5 mg/kg was
given on PN11–14. The same randomization
procedure was followed. Neither regimen
evokes weight loss or mortality (Campbell et al.
1997; Dam et al. 1998; Johnson et al. 1998;
Song et al. 1997), and in the present study we
did not observe any changes in suckling or
maternal caretaking. Samples were obtained on
PN60 as already described.
None of the prenatal or postnatal treat-
ment regimens evoked a signiﬁcant change in
weight of any of the brain regions on PN60
(data not shown).
5HT receptor and transporter binding.
Tissues were thawed and homogenized
(Polytron, Brinkmann Instruments, Westbury,
NY) in ice-cold 50 mM Tris (pH 7.4), and the
homogenates were sedimented at 40,000 × g
for 15 min. The pellets were washed twice by
resuspension (Polytron) in homogenization
buffer followed by resedimentation and were
then dispersed with a homogenizer (smooth
glass fitted with Teflon pestle) in the same
buffer.
Two radioligands (Perkin-Elmer Life
Sciences, Boston, MA) were used to determine
5HT receptor binding (Xu et al. 2002): 1 nM
[3H]8-hydroxy-2-(di-n-propylamino)tetralin
(specific activity, 135 Ci/mmol) for 5HT1A
receptors (Park et al. 1999; Stockmeier et al.
1998), and 0.4 nM [3H]ketanserin (specific
activity, 63 Ci/mmol) for 5HT2 receptors
(Leysen et al. 1982; Park et al. 1999). For
5HT1A receptors, incubations lasted 30 min
at 25°C in a buffer consisting of 50 mM
Tris (pH 8), 2 mM MgCl2, and 2 mM
sodium ascorbate; 400 µM 5HT (Sigma
Chemical Co., St. Louis, MO) was used to
displace specific binding. For 5HT2 recep-
tors, incubations lasted 15 min at 37°C in
50 mM Tris (pH 7.4), and specific binding
was displaced with 40 µM methylsergide
(Sandoz Pharmaceuticals, East Hanover,
NJ). Incubations were stopped by the addition
of excess of ice-cold buffer, and the labeled
membranes were trapped by rapid vacuum ﬁl-
tration onto glass fiber filters that were pre-
soaked in 0.05% polyethyleneimine (Sigma).
The ﬁlters were then washed repeatedly, and
radiolabeling was determined. For binding to
the presynaptic 5HT transporter (5HTT)
(McGrath et al. 1997; Moret and Briley 1991;
Slotkin et al. 1999b; Xu et al. 2001), the
membrane suspension was incubated with
85 pM [3H]paroxetine (specific activity,
19.4 Ci/mmol; Perkin-Elmer) with or without
addition of 100 µM 5HT to displace speciﬁc
binding. Incubations lasted 120 min at 20°C.
AC activity. We used the same membrane
preparation as for receptor binding assays, and
the methods have been described in detail pre-
viously (Slotkin et al. 1990, 1992, 2001b; Xu
et al. 2002). Membrane aliquots were incu-
bated 10 min at 30°C with ﬁnal concentrations
of 40 mM Tris-HCl (pH 7.4), 10 mM theo-
phylline, 1 mM adenosine 5´-triphosphate,
10 µM guanosine 5´-triphosphate, 2 mM
MgCl2, 1 mg/mL bovine serum albumin, and a
creatine phosphokinase-ATP–regenerating sys-
tem consisting of 10 mM sodium phosphocrea-
tine and 8 IU/mL phosphocreatine kinase, in a
total volume of 250 µL. The enzymatic reac-
tion was stopped by placing the samples in a
90–100°C water bath for 5 min, followed by
sedimentation at 3,000 × g for 15 min; the
supernatant solution was assayed for cyclic
AMP by radioimmunoassay (Amersham
Biosciences, Piscataway, NJ). AC activity was
evaluated under four different conditions: basal
activity; the response to 100 µM forskolin
(Sigma), which acts directly on AC, bypassing
the need for activation of neurotransmitter
receptors (Seamon and Daly 1986); and both
basal and forskolin-stimulated activity in the
presence of 100 µM 5HT. This approach
enables detection of potential inhibitory or exci-
tatory actions (Chow et al. 2000; Slotkin et al.
1999a; Xu et al. 2002). The concentrations of
all the agents used here have been found to be
optimal for effects on AC and/or were con-
firmed in preliminary experiments (Auman
et al. 2000, 2001; Xu et al. 2002; Zeiders et al.
1997, 1999).
Data analysis. Data are presented as
means and SEs obtained from eight animals
of each sex for each prenatal treatment group
and six animals per sex for each postnatal
treatment group; the only exceptions were
striatum for GD17–20 exposure and brain-
stem for PN11–14 exposure, both of which
had 12 animals per sex per treatment group.
For convenience, some of the results are given
as the percent change from control values, but
statistical evaluations were always conducted
on the original data. To establish treatment
differences in radioligand binding, a global
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Table 1. Binding parameters and AC activities in controls. 
Measure Cerebral cortex Hippocampus Striatum Midbrain Brainstem
5HT1A bindinga 88 ± 5b 358 ± 20 18 ± 1 39 ± 2 39 ± 1
5HT2 bindinga 152 ± 7 39 ± 1 133 ± 6 24 ± 1 27 ± 1
5HTT bindinga 347 ± 12 393 ± 18 640 ± 40 491 ± 12 376 ± 7
Basal ACc 183 ± 11 146 ± 7 139 ± 5 253 ± 10 139 ± 7
Forskolin-stimulated ACc 1,258 ± 60 663 ± 27 4,307 ± 122 962 ± 56 395 ± 13
Values were combined across multiple cohorts (controls used for CPF administration on GD9–12, GD17–20, PN1–4, and
PN11–14). However, statistical comparisons of the effects of CPF were made only with the appropriately matched control
cohort. Values shown are for males and females combined.
afmol/mg protein. bOnly one determination in one region showed a sex difference: 5HT1A binding in the cerebral cortex, male
77 ± 5 fmol/mg protein, female 98 ± 6 (p < 0.02). cpmol/min/mg protein.analysis of variance (ANOVA; data log trans-
formed whenever variance was heterogeneous)
was first conducted, incorporating all con-
tributing variables: dose, exposure period,
brain region, sex, and the three types of mea-
surements made on each membrane prepara-
tion (repeated measures, because each
membrane preparation was used for the mul-
tiple binding measurements). As justified by
signiﬁcant interactions of treatment with the
other variables, data were then subdivided to
permit testing of individual treatments and
measures that differed from control values.
These were conducted by lower-order
ANOVAs, followed, where appropriate, by
Fisher’s protected least-significant-difference
test to identify individual values for which the
CPF groups differed from the corresponding
control. However, in situations where there
was no interaction of treatment × other vari-
ables, only main treatment effects are reported
without conducting separate subtests. Effects
of CPF on the AC response to 5HT were
evaluated for effects on basal activity with or
without 5HT and on forskolin-stimulated
activity with or without 5HT. For all tests,
significance for main treatment effects was
assumed at p < 0.05; however, for interactions
at p < 0.1, we also examined whether lower-
order main effects were detectable after subdi-
vision of the interactive variables (Snedecor
and Cochran 1967).
For presentation (Table 1), control values
were combined across the different treatment
cohorts (controls used for CPF administration
on GD9–12, GD17–20, PN1–4, PN11–14).
However, statistical comparisons of the effects
of CPF were made only with the appropri-
ately matched control cohort.
Results
CPF treatment on GD9–12. For this treat-
ment regimen, across all three ligand binding
measurements and all regions, multivariate
ANOVA indicated a signiﬁcant main effect of
treatment (p < 0.0001) without any inter-
actions of treatment × other variables.
Exposure to the low dose of CPF elicited a sig-
nificant overall elevation of 5HT1A, 5HT2,
and 5HTT ligand binding without statistical
distinction by region, measure, or sex
(Figure 1A). Nevertheless, we veriﬁed that the
treatment effect was signiﬁcant in both males
(p < 0.006) and females (p < 0.004), in each
region (p < 0.02 in cerebral cortex, p < 0.003
in midbrain, p < 0.005 in brainstem), and for
each of the individual measures (p < 0.04 for
5HT1A receptors, p < 0.0003 for 5HT2 recep-
tors, p < 0.0001 for the 5HTT site).
To evaluate the potential role of systemic
toxicity in the effects on 5HT receptors and
5HTT, we also examined the effects of expo-
sure to a higher dose (5 mg/kg) that evokes
significant but transient maternal weight
deﬁcits but that still lies below the threshold
for fetal weight impairment (Qiao et al. 2002);
presumably, if the effects on 5HT systems in
adulthood are secondary to systemic toxicity
during the fetal exposure period, then the
higher dose should give a far more robust
effect. However, the effects were generally the
same at 5 mg/kg, showing overall statistical
significance from the control group but not
from the 1 mg/kg group and, again, without
interactions of treatment with other variables
(Figure 1B).
Accordingly, CPF exposure during this
early developmental period elicits lasting
changes in 5HT receptors and 5HTT in a
region containing major 5HT projections (cere-
bral cortex) as well as in regions containing
5HT cell bodies (midbrain, brainstem). In light
of the positive ﬁndings with this early develop-
mental treatment regimen, we expanded the
scope of the next studies to include two more
regions containing 5HT terminals ﬁelds, the
hippocampus and striatum.
CPF treatment on GD17–20. CPF admin-
istered during late gestation elicited statistically
robust effects assessed by global ANOVA
across all ligand binding measures and brain
regions, but in this case, the effect was interac-
tive with the other variables: p < 0.0001 for the
main treatment effect, p < 0.004 for treatment
× sex, p < 0.06 for treatment × measure,
p < 0.007 for treatment × sex × region, and
p < 0.0001 for treatment × region × measure.
Accordingly, the regions were examined sepa-
rately for main treatment effects and interac-
tions with the other variables.
The lower dose of CPF (1 mg/kg) does not
evoke signs of maternal or fetal systemic toxic-
ity and does not cause signiﬁcant inhibition of
fetal brain cholinesterase activity (Qiao et al.
2002). Nevertheless, we found robust effects
on 5HT receptors and on 5HTT binding
(Figure 2A). In fact, the effects were far larger
than those seen with the GD9–12 treatment
regimen (note the different ordinate scales in
Figures 1 and 2), with increases as large as
Article | Aldridge et al.
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Figure 1. Effects of GD9–12 CPF exposure on 5HT receptors and 5HTT in brain regions in adulthood (PN60),
presented as the percent change from control values (Table 1). (A)1mg/kg CPF (ANOVA: Rx, p < 0.0001).
(B)5mg/kg CPF (ANOVA: Rx, p < 0.002). Rx, treatment. Lower-order ANOVAs for each region, measure, or
sex or for individual values were not evaluated because of the absence of interactions of treatment with
the other variables.
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Female30–80% above control values in some regions.
In addition, the GD17–20 regimen displayed
differential effects according to the specific
brain regions, individual measures, and sex. By
far, the largest elevations were seen in the stria-
tum, which also showed a strong preferential
action in males. The other regions containing
5HT terminal ﬁelds, cerebral cortex and hip-
pocampus, also displayed signiﬁcant elevations
but on a far more modest scale, yet still compa-
rable with the magnitude of effect seen with
the GD9–12 regimen. In the cerebral cortex,
males were also affected signiﬁcantly more than
were females. The two regions containing 5HT
cell bodies (midbrain, brainstem) showed sig-
nificant increases of the same magnitude as
those in the cerebral cortex and hippocampus.
Although there were signiﬁcant differences in
the magnitude of CPF’s effect for each of the
ligand markers, all three showed significant
elevations in multiple regions.
As before, when the CPF dose was raised
above the threshold for maternal toxicity and
fetal cholinesterase inhibition (5 mg/kg), the
effects were still present overall but were not
greater than those seen at the lower dose. In
fact, most of the effects were smaller for
5 mg/kg than for 1 mg/kg, indicating that
systemic toxicity, if anything, tends to reduce
receptor and transporter expression rather
than contributing to the increases.
CPF treatment on PN1–4. For the three
binding parameters, multivariate ANOVA indi-
cated a main effect of CPF treatment
(p < 0.0001) that was interactive with all the
other variables: p < 0.0002 for treatment × sex,
p < 0.0001 for treatment × region, p < 0.0003
for treatment × measure, and p < 0.0007 for
treatment × region × measure. Accordingly, the
data were subdivided for lower-order analyses.
As found with the prenatal exposure regi-
mens, postnatal CPF treatment produced an
overall elevation of 5HT ligand parameters in
adulthood, and as found for the GD17–20
treatment, the effects tended to be greater in
males than in females (Figure 3). Modest
effects were seen in the cerebral cortex and
hippocampus, whereas substantially larger
alterations were seen in the striatum. Notably
in this case, actions in the regions containing
5HT cell bodies, the midbrain and brainstem,
were among the most robust. There was one
additional difference from the effects of the
prenatal treatment regimens: 5HTT binding
was reduced in females in all regions except
the brainstem. Although only the cerebral
cortex showed an individually signiﬁcant dif-
ference, the magnitude of this effect was com-
parable in hippocampus, striatum, and
midbrain, and statistical evaluations across
these four regions showed a signiﬁcant main
effect of treatment (p < 0.002) without a
treatment × region interaction. The brain-
stem was unique in showing global elevations
of 20–30% for all three measures in both
sexes.
CPF treatment on PN11–14. ANOVA
across the three ligand binding measures indi-
cated a signiﬁcant interaction of treatment ×
sex (p < 0.04) and treatment × region × sex
× measure (p < 0.007), necessitating examina-
tion of lower-order effects (Figure 4).
In general, the effects of this treatment
regimen were smaller than the others, with
statistical significance found only in two of
the regions containing 5HT terminals (cere-
bral cortex, striatum) and in neither of the
regions containing the cell bodies (midbrain,
brainstem). Although only two individual
measurements displayed statistical signifi-
cance, there was a clear distinction of the
effects on 5HTT between the regions with
5HT terminals and those with cell bodies. In
females, 5HTT binding was significantly
reduced across the cerebral cortex, hippocam-
pus, and striatum (p < 0.007), whereas it was
unaffected in the midbrain and brainstem. As
was seen with the PN1–4 regimen, this effect
was not shared by males.
Effects on AC signaling. In comparison
with the robust effects of the different CPF
regimens on 5HT receptors and 5HTT, alter-
ations in AC signaling tended to be much less
remarkable. CPF exposure on GD9–12 or on
GD17–20 had no significant effect on basal
or forskolin-stimulated AC activities in the
absence of added 5HT (data not shown).
With the PN1–4 regimen, across all brain
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Figure 2. Effects of GD17–20 CPF exposure on 5HT receptors and 5HTT in brain regions in adulthood (PN60),
presented as the percent change from control values (Table 1). (A)1   mg/kg CPF. (B)5mg/kg CPF.
Abbreviations: NS, not significant; Rx, treatment. Note the different ordinate scale from that in Figure 1.
ANOVAs across all regions and measures and across both sexes are as follows: (A), Rx, p < 0.0001; Rx × sex,
p < 0.02; Rx × region, p < 0.0001; Rx × sex × region, p <0 .002; Rx × measure, p <0 . 06; Rx × region × measure,
p < 0.0001; (B), Rx, p < 0.0001; Rx × sex, p < 0.002; Rx × sex × region, p < 0.1. ANOVAs for each region appear
within the ﬁgure. Where the test for a given region did not indicate a treatment × measure interaction, only
the main effect across the three measures was compiled. In the presence of a treatment × measure inter-
action, separate statistical evaluations were conducted for each ligand. 
*Individual measures for which the CPF groups differ signiﬁcantly from the corresponding control, grouped either across
both sexes (in the absence of a treatment × sex interaction, indicated by an asterisk over a line connecting male and
female values) or individually for males and females (where a treatment × sex interaction was detected).regions, CPF exposure elicited a sex-related
alteration in basal AC activity in the absence
of added 5HT (treatment × sex, p < 0.03), but
no signiﬁcant differences values were separated
by sex; there were no signiﬁcant differences in
forskolin-stimulated AC activities in the
absence of added 5HT (data not shown). CPF
exposure on PN11–14 had a signiﬁcant main
treatment effect on basal AC in the absence of
added 5HT (p < 0.004), but the difference
represented an average reduction of only 7%
(data not shown). There was a similar effect
on forskolin-stimulated AC (7% reduction,
p < 0.009).
We evaluated the effects of 5HT on AC
activity under two standard conditions: effects
on basal AC and effects on forskolin-stimulated
AC, so as to detect either stimulation or inhibi-
tion of activity (Chow et al. 2000; Slotkin et al.
1999a; Xu et al. 2002). For 5HT effects on
basal activity, the only treatment effect was
obtained in the brainstem after PN1–4 CPF
exposure; there was a signiﬁcant treatment × sex
interaction (p < 0.05), but neither sex displayed
a significant main effect of CPF treatment
when examined separately (data not shown).
For the GD9–12 regimen, we also did not see
any effect of CPF treatment on the 5HT
response of forskolin-stimulated AC (data not
shown), but there were signiﬁcant effects for all
the other treatment regimens.
CPF exposure on GD17–20 elicited
changes in the AC response to 5HT in the
cerebral cortex and midbrain. In the cerebral
cortex of control rats, 5HT exerted a net
inhibitory effect on forskolin-stimulated AC
activity, evidenced by a reduction in the ratio
of activity with or without 5HT (Figure 5A).
Low-dose (1 mg/kg) CPF exposure elicited a
reduction in 5HT in males but intensiﬁed the
inhibitory effect in females. Raising the dose
above the threshold for systemic toxicity
(5 mg/kg) did not intensify the effect and
actually reduced it (data not shown). In the
midbrain, the inhibitory effect of 5HT was
reversed in females, and no signiﬁcant differ-
ences were seen in males (Figure 5B).
CPF exposure on PN1–4 had a small but
statistically signiﬁcant effect on AC signaling
in the brainstem (Figure 5C), and again,
females were affected but males were not. In
this region, the CPF group displayed a shift
from a net stimulatory response to 5HT to
an inhibitory response. The PN11–14 treat-
ment regimen affected the AC response to
5HT in the striatum (Figure 5D), with a sig-
nificant overall intensification of the
inhibitory response.
Discussion
Previous work demonstrated that exposure of
fetal or neonatal rats to CPF elicits immediate
alterations in 5HT receptors and their ability
to modulate cell signaling, as well as in the
expression of the high-affinity presynaptic
5HTT (Aldridge et al. 2003; Raines et al.
2001). In the present study, we found pertur-
bations of 5HT synaptic components and
5HT-mediated responses in adult rats after
CPF exposure in developmental windows
ranging from the neural tube stage through
the second postnatal week, with effects noted
even at exposures below the threshold for any
signs of maternal, fetal, or neonatal toxicity.
These long-term perturbations of 5HT synap-
tic function display distinct regional and sex
selectivities that change according to the spe-
ciﬁc period of exposure. It is therefore highly
unlikely that CPF acts globally to increase or
decrease the expression of the corresponding
receptor, transporter, or signal transduction
proteins, because in that case the same effects
would be seen in every region, with every
exposure window, and in both sexes. Rather,
our results suggest that CPF alters the “pro-
gram” for development of 5HT innervation
with consequent effects on specific synaptic
populations. In support of this view, although
some of the features of the long-term effects of
CPF on 5HT systems seen here mirror those
found in the immediate posttreatment period
(Aldridge et al. 2003; Raines et al. 2001),
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Figure 4. Effects of PN11–14 CPF (5 mg/kg) exposure on 5HT receptors and 5HTT in brain regions in adult-
hood (PN60), presented as the percent change from control values (Table 1). Abbreviations: NS, not signif-
icant; Rx, treatment. ANOVAs across all regions and measures and across both sexes are as follows: Rx ×
sex, p < 0.04; Rx × region × sex × measure, p < 0.007; ANOVAs for each region appear within the ﬁgure.
*Individual values for which the CPF group differs signiﬁcantly from the control. 
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Figure 3. Effects of PN1–4 CPF exposure (1 mg/kg) on 5HT receptors and 5HTT in brain regions in adulthood
(PN60), presented as the percent change from control values (Table 1). Abbreviations: NS, not signiﬁcant; Rx,
treatment. ANOVAs across all regions and measures and across both sexes are as follows: Rx, p < 0.0001; Rx
× sex, p < 0.0002; Rx × region, p < 0.0001; Rx × measure, p < 0.0003; Rx × region × measure, p < 0.0007;
ANOVAs for each region appear within the ﬁgure. Where the test for a given region did not indicate a treat-
ment × measure interaction, only the main effect across the three measures was compiled. In the presence
of a treatment × measure interaction, separate statistical evaluations were conducted for each ligand.
*Individual measures for which the CPF groups differ signiﬁcantly from the corresponding control, grouped either across
both sexes (in the absence of a treatment × sex interaction, indicated by an asterisk over a line connecting male and
female values) or individually for males and females (where a treatment × sex interaction was detected).
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many of them do not, and these are detailed
and discussed below.
With CPF exposure during neurulation
(GD9–12), we found a small (~10%) but sig-
niﬁcant promotional effect on 5HT receptors
and the 5HTT site, without any selectivity for
brain region or sex, and absent any corre-
sponding alteration in 5HT-mediated AC sig-
naling. In contrast, the initial posttreatment
effects of this regimen are inhibitory for
expression of the receptors and transporter in
only one brain region (brainstem), followed
shortly thereafter by elevations similar to those
found here, accompanied by enhanced inhibi-
tion of AC by 5HT (Aldridge et al. 2003).
Thus, for this exposure period, the effects on
5HT synaptic parameters in adulthood do not
correspond to the immediate fetal effects.
For exposure on GD17–20, we found
markedly larger, global increases in receptor
and transporter expression, with emergence of
sex and regional selectivities; the largest effects
were seen in the regions with 5HT terminal
projections, especially the striatum, and males
were affected far more than were females. In
this case, the effects in adulthood do match up
well with those seen in the immediate post-
treatment period, in terms of both the ubiqui-
tous regional effects and the much larger
magnitude of up-regulation (Aldridge et al.
2003). However, the effects on 5HT modula-
tion of AC activity were totally distinct. First,
unlike the receptor alterations, the shifts in
adult signaling proﬁles were more prominent
in females. Second, there were disjunct effects
in a region with 5HT terminals compared with
one containing primarily 5HT cell bodies
(midbrain): 5HT-induced inhibition was
enhanced in females in the cerebral cortex,
whereas the response was reduced in the mid-
brain. Evidently, factors other than the concen-
tration of 5HT receptors play a critical role in
transduction of the receptor signal, an interpre-
tation that is consonant with conclusions
reached for other AC-linked receptors (Gao
et al. 1998, 1999; Navarro et al. 1991). We are
currently investigating the effects of early CPF
exposure on development and function of the
individual transduction proteins of the AC sig-
naling cascade in order to clarify this issue.
With CPF exposure in the early postnatal
period (PN1–4), we still found robust changes
in 5HT receptors, and as with the GD17–20
treatment paradigm, males were affected much
more than were females. There were some
notable differences between the two regimens,
however. With PN1–4 exposure, the regions
with 5HT cell bodies (midbrain, brainstem)
were affected far more than with the earlier
treatment. In addition, deﬁcits in the 5HTT
site now emerged in females. Effects on 5HT
modulation of AC were quite minor but still
showed preferential effects in females. When
the exposure was shifted to an even later period
(PN11–14), the effects on receptor expression
were far less notable, but there was still a sex-
selective (female) reduction in the 5HTT site
in brain regions containing the nerve terminals;
AC signaling showed an enhanced inhibitory
effect of 5HT in both sexes. Again, the effects
of postnatal CPF exposures assessed in adult-
hood match some but not all aspects of their
immediate effects on 5HT systems (Aldridge
et al. 2003; Raines et al. 2001).
In general, then, our results indicate three
distinct response families of long-term alter-
ations in 5HT systems elicited by develop-
mental CPF exposure. First, there is an
enhancement of 5HT receptor expression,
with peak effects elicited in the late gestational
to early postnatal period, and preferential
effects in males. Second, there are biphasic
alterations in the 5HTT site: promotional
effects elicited by gestational exposure but
inhibition in regions containing 5HT termi-
nal zones when exposure is shifted to the
postnatal period. This pattern makes sense in
light of the adverse effects of CPF on axono-
genesis and synaptogenesis (Barone et al.
2000; Das and Barone 1999; Li and Casida
1998; Song et al. 1998), events that are most
active postnatally in the rat (Rodier 1988).
Third, there are smaller but signiﬁcant effects
on 5HT modulation of cell signaling that are
entirely distinct from those on the 5HT recep-
tors, in terms of both sex dependence and
regional selectivity, but sharing a similar peak
of sensitivity in the late gestational phase.
Accordingly, the developing brain is sensitive
to CPF-induced disruption of 5HT synaptic
function at virtually all stages, with the pattern
of effects shifting from global actions to more
focal, sex-selective effects as maturation pro-
ceeds. Overall, however, the greatest long-term
alterations appear to be concentrated in the
late gestational to early postnatal period, a
developmental stage in the rat that parallels
the second trimester of human fetal brain
development (Rodier 1988).
One question that is still unanswered is
whether CPF speciﬁcally targets 5HT systems
or whether the effects represent inclusion of
5HT in the spectrum of neurochemical alter-
ations secondary to its adverse effects on neural
cell replication, differentiation, and synaptic
outgrowth (Barone et al. 2000; Pope 1999;
Rice and Barone 2000; Slotkin 1999, In press).
CPF interacts directly with 5HT transport
(Sachana et al. 2001) and elicits profound,
immediate effects on fetal and neonatal 5HT
systems during exposure (Aldridge et al. 2003).
At the same time, CPF affects development of
Figure 5. Alterations in the AC response to 5HT in adulthood (PN60) after CPF exposure during different
developmental periods; normative AC activities in the absence of 5HT are presented in Table 1. Rx, treatment.
Only the treatments and regions showing a signiﬁcant difference are presented: GD17–20 exposure, cerebral
cortex (A) and midbrain (B); PN1–4 exposure, brainstem (C); PN11–14, striatum (D). The response to 5HT was
determined as the ratio of activity with 5HT to activity without 5HT; thus, a ratio > 1 denotes stimulation,
whereas a ratio < 1 denotes inhibition. ANOVAs across treatment and sex are as follows: (A), Rx × sex,
p < 0.0004; (B), Rx × sex, p < 0.003; (C), Rx × sex, p < 0.03; (D), Rx, p < 0.04. Where a signiﬁcant treatment × sex
interaction was detected, separate tests were carried out for each sex; in the absence of an interaction, only
the main effect of treatment was compiled.
*Individual values for which the CPF group differs signiﬁcantly from the control.
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CPF 5 mg/kgother neurotransmitter systems that converge
on the same signaling pathways as 5HT
(Auman et al. 2000; Huff and Abou-Donia
1995; Huff et al. 1994, 2001; Ward and
Mundy 1996; Zhang et al. 2002), as well as
eliciting heterologous effects on the G-proteins
that couple receptors to AC, or on AC itself
(Auman et al. 2000; Garcia et al. 2001; Olivier
et al. 2001; Song et al. 1997). It may thus be
difﬁcult to isolate a speciﬁc mechanism when it
is most likely that there are multiple mecha-
nisms superimposed on each other that medi-
ate the net effect of CPF on any given
neurotransmitter pathway. Nevertheless, the
effects on 5HT systems by CPF represent an
important end point, in light of the role of this
neurotransmitter in appetitive and affective
disorders. Accordingly, it will be vital to
expand the spectrum of outcomes evaluated for
CPF to include 5HT-related behaviors.
In our earlier studies (Aldridge et al. 2003;
Dam et al. 2000; Garcia et al. 2002; Icenogle
et al. In press; Levin et al. 2001, 2002; Meyer
et al. 2003; Qiao et al. In press; Slotkin et al.
2001a, 2002), we found that sex differences in
the effects of CPF emerged only when expo-
sure occurred in late gestation or in the neona-
tal period, and not with exposure during
neurulation (GD9–12). The present ﬁndings
for 5HT systems showed the same critical
period for sex selectivity. CPF lacks sufﬁcient
estrogenic activity to account directly for these
effects (Andersen et al. 2002; Vinggaard et al.
2000), but it does interfere with testosterone
catabolism (Usmani et al. 2003); further-
more, with exposures above the threshold for
systemic toxicity, CPF evokes secondary
endocrine alterations, so a marginal effect at
the lower exposures here might contribute to
sex differences in outcome (Guven et al. 1999).
Nevertheless, because the critical period found
here corresponds to the commencement of sex-
ual differentiation of the brain (McCarthy
1994; Mong and McCarthy 1999) and speciﬁ-
cally involves the cyclic AMP pathway (Auger
2003), CPF effects on brain development are
themselves likely to inﬂuence sexual differenti-
ation and resultant sex-related outcomes.
The present ﬁndings indicate that fetal or
neonatal exposure to CPF alters the program
for development of 5HT synaptic function,
thus affecting 5HT systems in adulthood and
extending the effects of CPF beyond choliner-
gic neurotransmission. Serotonergic dysfunc-
tion is involved in appetitive and affective
disorders, so our results are consonant with
suggestions that at least some of the incidence
of these disturbances may have contributions
from environmental neurotoxicant exposures
(Slikker and Schwetz 2003; Toschke et al.
2002; von Kries et al. 2002). On the surface, it
seems unlikely that these effects, by themselves,
would trigger such multifactorial diseases, but
certainly they might confer additional risk that
acts in concert with other factors. Studies of
CPF effects on 5HT-related behaviors, espe-
cially those operating in animal models of
depression or obesity, will be needed to clarify
the outcomes of the long-term alterations in
5HT synaptic function identiﬁed here.
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